Separate and combined effects of long-term GIP and GLP-1 receptor activation in patients with type 2 diabetes: a structured summary of a study protocol for a double-blind, randomised, placebo-controlled clinical trial

INTRODUCTION: Due to reports of severely reduced insulinotropic effect of the incretin hormone glucose-dependent insulinotropic polypeptide (GIP) in type 2 diabetes (T2D), GIP has not been considered therapeutically viable. Recently, however, tirzepatide, a novel dual incretin receptor agonist (acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Helsted, Mads M, Gasbjerg, Lærke S, Vilsbøll, Tina, Nielsen, Casper K, Forman, Julie L, Christensen, Mikkel B, Knop, Filip K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Diabetes and Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972408/
https://www.ncbi.nlm.nih.gov/pubmed/36849212
http://dx.doi.org/10.1136/bmjopen-2022-065736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972408/
https://www.ncbi.nlm.nih.gov/pubmed/36849212
http://dx.doi.org/10.1136/bmjopen-2022-065736

Ejemplares similares